CS and malaria: Thus, to enhance the CD8+ T cell response of a CS-based immunization procedure, in this investigation we compared in mice the immunogenicity and anti-malaria efficacy of protocols based on priming with parvovirus PPV-VLPs carrying a CD8+ T-cell epitope from the P. yoelii CS protein, restricted by the H-2Kd molecule (SYVPSAEQI) and boosted with either a recombinant replication competent (WR strain) or replication restricted (MVA strain) of VACV, both vectors expressing the entire P. yoelii CS protein.